Global Pediatric Antibiotics Market, By Infection (Acute Sinusitis, Acute Otitis Media, Non-Specific Upper Respiratory Tract Infections, Urinary Tract Infections and Others), By Route Of Administration (Oral, Topical, Intravenous and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies and E-Commerce) and By Region (North America, Latin America, Europe, Asia-Pacific, Middle East & Africa) is estimated to be valued at US$ 6,478.9 Mn in 2022 and is expected to exhibit a CAGR of 2.3% during the forecast period (2022-2030), as highlighted in a new report published by Coherent Market Insights.
Key trends in market include increasing prevalence of bacterial infections among children and deaths associated with it demands antibiotics for prevention which is expected to drive market growth over the forecast period. For instance, according to data published by WHO (World Health Organization) in November 2021, pneumonia accounted for 14% of all deaths of children under 5 years of age, killing 740,180 children in 2019 globally. Pneumonia is caused by a number of infectious agents, including bacteria, viruses, and fungi.
Global Pediatric Antibiotics Market– Impact of Coronavirus (COVID-19) Pandemic
The COVID-19 pandemic caused major disruptions to clinical trial executions in the U.S., impacting key stakeholders across the healthcare industry. Investigative site capabilities experienced disturbances, driven by staff furloughs, social-distancing protocols, financial losses, and concerns over patient safety. Sponsors, contract research organizations, and other organizations that support drug development shifted to remote working environments. Recently, the U.S. Food and Drug Administration (FDA) guidance (March 2020 and updated on July 2020) acknowledged that the impact of COVID-19 may require companies conducting clinical trials to consider virtual patient visits or include novel ways for conducting clinical trials in place of current protocols. Therefore, there are now more opportunities for using remote healthcare including conducting virtual or decentralized trials, site-less clinical trials, and use of other non-traditional approaches that do not involve in-person visits. Moreover, regulatory bodies are focusing on imposing the guidelines to prevent the spread of COVID-19 infection while conducting clinical trials on participants/subjects. According to the U.S. Food Drug and Administration report 2020, clinical trials performed by the companies and research institutes during the COVID-19 should follow the guidelines prescribed by the U.S. FDA , which are as follows: The participants in the clinical trials should undergo COVID-19 screening procedures to avoid the spread of COVID-19 infections during clinical trials, The participants are not allowed to visit the investigational site, and sponsors should evaluate alternative methods for contacting the participants/subjects through various methods such as phone contact, virtual visit, alternative location for assessment, including local labs or imaging centers and the sponsors should plan the visit of the participants to the investigational site to avoid the spread of COVID-19 infection. Moreover, to study the impact of COVID-19 on clinical trial studies on drugs, various research institutes are conducting survey studies to understand the impact of COVID-19 on ongoing clinical trials, globally. For instance, on April 23, 2020, Medidata technology and solutions, a global platform that supports clinical trials, performed an electronic (video conference) survey of 9,952 staff at various trial investigator sites, globally. The survey had a low response rate of 10.3%, as only few respondents answered the survey in a total of 1,030 participants. Most of the respondents in the survey were from the U.S. (North America; 58.3%), followed by Asia Pacific (23.8%), Europe (8.1%), South & Central America (7.1%), and Middle East & Africa (2.7%). The respondents included in the study were study coordinators, investigators, site managers/directors, clinical nurses, and others. The survey results showed that the ability to conduct ongoing clinical trials during the COVID-19 pandemic had affected 69%, whereas 78% mentioned that this situation affected the initiation of new trials.
Browse 30 Market Data Tables and 34 Figures spread through 176 Pages and in-depth TOC on “Global Pediatric Antibiotics Market”- Forecast to 2030, Global Pediatric Antibiotics Market, By Infection (Acute Sinusitis, Acute Otitis Media, Non-Specific Upper Respiratory Tract Infections, Urinary Tract Infections and Others), By Route Of Administration (Oral, Topical, Intravenous and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies and E-Commerce) and By Region (North America, Latin America, Europe, Asia-Pacific, Middle East & Africa)
To know the latest trends and insights prevalent in this market, click the link below:
https://www.coherentmarketinsights.com/market-insight/pediatric-antibiotics-market-5190
Moreover, increasing prevalence of bacterial infections among children and deaths associated with it demands antibiotics for prevention which is expected to drive market growth over the forecast period. For instance, in June 2022, Dolly Parton an American singer-songwriter, had donated US $1 million to Vanderbilt University Medical Center in Nashville, aimed at helping pediatric infectious disease research. The donation will fund research tackling disease causes, understanding and prevention of antibiotics resistance, prevention and treatment of infection, and diagnosis and treatment of infections in children with cancer.
Key Takeaways of the Global Pediatric Antibiotics Market:
- Global pediatric antibiotics market is expected to exhibit a CAGR of 2.3% during the forecast period due to increasing government initiative for promoting better health care facilities for children in emerging economies to which is expected to boost growth of market. For instance, in November 2020, The Ministry of Public Health, Africa had announced the launch of Project AVENR. AVENIR aims to reduce mortality and morbidity in children under five in Niger through mass drug administration of azithromycin every six months. Azithromycin is used to treat different types of infections caused by bacteria, such as respiratory infections, skin infections, ear infections, etc.
- Among End Users, Hospital Pharmacy segment is estimated to exhibit highest CAGR in the global pediatric antibiotics market over the forecast period, owing to increasing prevalence of bacterial infection in children. For instance, according to data published by National Center for Biotechnology Information in January 2021, although acute otitis media can occur at any age, it is most commonly seen between the ages of 6 to 24 months. Approximately 80% of all children will experience a case of otitis media during their lifetime, and between 80% and 90% of all children will have otitis media with an effusion before school age globally.
- On the basis of the region, Asia Pacific is estimated to exhibit largest CAGR in the global pediatric antibiotics market over the forecast period, owing to increasing funding to develop and deliver treatments for drug-resistant infections. For instance, in March 2022, the Global Antibiotic Research and Development Partnership (GARDP) announced that it had received funding from the Government of Australia to support its critical work in developing and delivering treatments for drug-resistant infections.
- Major players operating in the global pediatric antibiotics market are Johnson & Johnson, Astellas Pharma, Inc, Pfizer Inc., Novartis AG, Bayer AG, Bristol-Myers Squibb Company, Abbott., DAIICHI SANKYO COMPANY, LIMITED, Dr. Reddy’s Laboratories Ltd, Teva Pharmaceuticals USA, Inc., Aurobindo Pharma USA, GlaxoSmithKline Plc., Hikma Pharmaceuticals PLC, Cipla Inc., Glenmark Pharmaceuticals, and Torrent Pharmaceuticals Ltd.
